Locations:
Search
Many approaches won’t delay therapy
Will cancer vaccine boost immunotherapy’s efficacy?
A closer look at the innovative procedure
When to change treatment strategy
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
A Cleveland Clinic oncologist’s book reflects on patients’ and physicians’ shared journeys
Durvalumab monotherapy appears safe and well-tolerated
Phase I study also reveals possible resistance mechanisms to HER2 antibodies
Encouraging clinical efficacy with no rise in adverse events
Initiative improves access to specialists, advanced treatments
Study compares outcomes of minimally invasive interval debulking and laparotomy
Advertisement
Advertisement